Total amount: € 0,00
A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413
Online ISSN 1827-1936
Li S. 1, Peck-Radosavljevic M. 2, Kienast O. 1, Preitfellner J. 1, Havlik E. 3, Schima W. 4, Traub-Weidinger T. 1, Graf S. 5, Beheshti M. 1, Schmid M. 2, Angelberger P. 6, Dudczak R. 1
1 Department of Nuclear Medicine Medical University of Vienna, Vienna, Austria
2 Department of Internal Medicine IV Division of Gastroenterology and Hepatology Medical University of Vienna, Vienna, Austria
3 Institute for Biomedical Technology and Physik Medical University of Vienna, Vienna, Austria
4 Department of Radiology, Medical University of Vienna, Vienna, Austria
5 Department of Internal Medicine II, Division of Cardiology Medical University of Vienna, Vienna, Austria,
6 Austrian Research Center, Seibersdorf, Austria
Aim. Imaging with radiolabelled vascular endothelial growth factor (VEGF) has been developed for the localisation and diagnosis of a variety of human solid tumors including gastrointestinal tumors.
Methods. In this study we investigated the biodistri-
bution, safety and absorbed dose of iodine-123 radiolabelled VEGF165 (123I-VEGF165) in 9 patients with pancreatic carcinoma. Following intravenous administration of 123I-VEGF165 (189±17 MBq; <130 pmole (<5 μg) VEGF165 per patient), sequential images were recorded during the initial 30 min PI. Serial whole-body images were acquired in anterior and posterior views at various time points. All patients underwent single-photon emission tomography (SPET) imaging. Dosimetry calculations were performed on the basis of γ camera data. Estimates of radiation absorbed dose were calculated using the MIRDOSE 3 program.
Results. The highest absorbed organ doses were found to be thyroid (0.058±0.004 mGy/MBq), spleen (0.046± 0.017 mGy/MBq), urinary bladder (0.04±0.02 mGy/MBq), lungs (0.034±0.009 mGy/MBq) and kidneys (0.033±0.005 mGy/MBq). The effective dose was estimated to be 0.017±0.002 mSv/MBq. A majority of primary pancreatic tumors and their metastases were visualized by 123I-VEGF165 scan.
Conclusion. In vitro binding results confirmed specific binding of 123I-VEGF165 to pancreatic tumor cells and tissues. 123I-VEGF165 shows favorable dosimetry and is a safe radiopharmaceutical that may be of potential value for the imaging of VEGF receptor status in vivo.